✦ LIBER ✦

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial

✍ Scribed by Hans C. Rümke; José-María Bayas; José-Ramón de Juanes; Covadonga Caso; Jan Hendrik Richardus; Magda Campins; Lars Rombo; Xavier Duval; Viktor Romanenko; Tino F. Schwarz; Rustem Fassakhov; Francisco Abad-Santos; Frank von Sonnenburg; Mamadou Dramé; Roland Sänger; W. Ripley Ballou

Book ID: 116960421
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 339 KB
Volume: 26
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2008.02.068

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and immunogenicity of an MF59®-ad

Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly

✍ Timo Vesikari; Aino Forstén; Karl-Heinz Herbinger; Giovanni Della Cioppa; Jenny 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 497 KB

A Phase III, randomized study to evaluat

A Phase III, randomized study to evaluate the immunogenicity and safety of an MF59®-adjuvanted A/H1N1 pandemic influenza vaccine in HIV-positive adults

✍ Diaz, Ricardo Sobhie; Tenore, Simone Barros; da Silva, Mônica M. Gomes; da Cunha 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 515 KB

Safety and immunogenicity of an inactiva

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial

✍ Jiangtao Lin; Jiansan Zhang; Xiaoping Dong; Hanhua Fang; Jiangting Chen; Nan Su; 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 135 KB

Immunogenicity, reactogenicity, and safe

Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: A phase III, randomized trial

✍ Tinoco, Juan Carlos; Pavia-Ruz, Noris; Cruz-Valdez, Aurelio; Aranza Doniz, Carlo 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 603 KB

Pediatric Safety Evaluation of An AS-Adj

Pediatric Safety Evaluation of An AS-Adjuvanted H5N1 Prepandemic Candidate Vaccine in Children Aged 3–9 Years: A Phase II Study

✍ A. Ballester; M. Garcés-Sánchez; M.V. Planelles Cantarino; M. Dramé; N. Bouveret 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 54 KB

A Novel Intramuscular Bivalent Norovirus

A Novel Intramuscular Bivalent Norovirus Virus-Like Particle Vaccine Candidate--Reactogenicity, Safety, and Immunogenicity in a Phase 1 Trial in Healthy Adults

✍ Treanor, J. J.; Atmar, R. L.; Frey, S. E.; Gormley, R.; Chen, W. H.; Ferreira, J 📂 Article 📅 2014 🏛 University of Chicago Press 🌐 English ⚖ 601 KB